Pulmatrix said that based on final results from a Phase 1/1b study of its Pulmazole (PUR1900) itraconazole DPI, which it is developing for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients, the company now plans to begin a Phase 2 trial by the end of the year.
The company previously reported top line data from the study showing that the formulation was safe and well tolerated, with low systemic exposure compared to oral itraconazole, in healthy volunteers and in asthma patients.
Pulmatrix Chief Medical Officer Jim Roach commented, “With the phase 1 study results now firmly in hand, we remain very enthusiastic about the potential for Pulmazole to address the significant limitations associated with oral itraconazole, and more importantly, to address the significant unmet medical need that patients with asthma and ABPA currently face. We believe that these results strongly support the further advancement of Pulmazole into Phase 2 and look forward to getting our next study underway next month.”
Read the Pulmatrix press release.
